RBC Capital: 'On balance we think readthroughs from the GSK acquisition of NUVB's key competitor are positive'
Tweet Send to a Friend
RBC Capital analyst Leonid Timashev reiterated an Outperform rating and $20.00 price target on Nuvation Bio Inc (NYSE: NUVB).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
